BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) ( www.BSDMedical.com), a leading provider of medical systems that utilize targeted heat therapy to treat cancer, today announced growing interest in hyperthermia at the 2012 international conference of the American Society for Radiation Oncology (ASTRO). ASTRO is the largest radiation oncology society in the world, and the annual conference is the premier worldwide scientific meeting in radiation oncology. The theme of the 2012 meeting was “Advancing Patient Care Through Innovation.”
BSD offers technologically innovative products that provide targeted heat therapy for the treatment of cancer. Hyperthermia has been shown to be the most potent radiosensitizing agent known to date and has demonstrated the ability to increase the effectiveness of radiation and many chemotherapeutic agents for certain tumors.
“Exhibiting at ASTRO allowed BSD to showcase the Company’s hyperthermia technology to interested physicians and distributors throughout the world,” stated Harold R. Wolcott, President of BSD Medical. “We were pleased with the increased level of interest in hyperthermia shown by both the U.S. and the international medical community and distributors.”
About ASTROASTRO is the largest radiation oncology organization of its kind and has more than 10,000 members. Their members include radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists and biologists, the medical professionals that are part of the medical teams that treat more than 1 million cancer patients each year. ASTRO is committed to excellence in patient care through a team-based approach to treatment. About the BSD Hyperthermia Systems The BSD-500 Hyperthermia System (BSD-500) is used to deliver therapeutic, targeted heat therapy (hyperthermia) using either non-invasive (external) or interstitial (internal) applicators. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors. Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV